1. Home
  2. NOTE vs SKYE Comparison

NOTE vs SKYE Comparison

Compare NOTE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

N/A

Current Price

$1.00

Market Cap

15.9M

Sector

Technology

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$0.73

Market Cap

44.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOTE
SKYE
Founded
2013
2012
Country
United States
United States
Employees
439
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
44.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
NOTE
SKYE
Price
$1.00
$0.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$29.25
$14.75
AVG Volume (30 Days)
572.6K
205.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
86.41
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.68
52 Week High
$5.59
$5.75

Technical Indicators

Market Signals
Indicator
NOTE
SKYE
Relative Strength Index (RSI) 41.58 38.62
Support Level $0.50 $0.68
Resistance Level $1.34 $0.83
Average True Range (ATR) 0.13 0.05
MACD 0.01 0.01
Stochastic Oscillator 18.85 8.16

Price Performance

Historical Comparison
NOTE
SKYE

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: